A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

ABSTRACT: This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or metastatic solid tumors with a KRAS G12C mutation.

DISEASE(S): Colorectal Cancer,Advanced Solid Tumors,Non-small Cell Lung Cancer,Colorectal Neoplasms,Carcinoma, Non-small-cell Lung

PROVIDER: 2343954 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR